Drug Detail

Information about MK-0646

Generic Name
IND
MK-0646
Brand Name (US)
Manufacturer
Merck
Drug Type
monoclonal antibody
Delivery
Intravenous
Approval Status
Phase 2
Indications
Overall Strategy
GIST cell based
Strategy
Block related tumor signal paths
Drug Category
IGF1R inhibitor

This is a IGF1R inhibitor in early development. IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs.
Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.


Links


Trials of this drug


Trial results


Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed